Tiger Brokers

US StockDetailed Quotes
Provided by Tiger Trade Technology Pte. Ltd.

Defiance Daily Target 2X Short LLY ETF

8.57
0.0000
Volume:- -
Turnover:- -
Market Cap:1.54M
PE:- -
High:8.57
Open:8.57
Low:8.57
Close:8.57
52wk High:21.15
52wk Low:7.63
Shares:180.00K
Float Shares:180.00K
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

OverviewCompanyNewsFilings

Kroger to Offer Eli Lilly's Zepbound KwikPen With Expanded Access to Savings Program

Dow Jones
·
Mar 13

Kroger Brings Zepbound® Kwikpen to Retail Pharmacy, Expanding Access and Savings for Self-Pay Patients

THOMSON REUTERS
·
Mar 13

Eli Lilly & Co (LLY) Receives a Buy from Bernstein

TIPRANKS
·
Mar 13

Sector Update: Health Care Stocks Retreat Late Afternoon

MT Newswires Live
·
Mar 13

Sector Update: Health Care Stocks Lower in Afternoon Trading

MT Newswires Live
·
Mar 13

Lilly finds impurity in compounded version of its weight-loss drug, warns of health risks

Reuters
·
Mar 13

Eli Lilly Cautions Against Blending Tirzepatide with Other Substances

Stock News
·
Mar 12

ProQR FY 2025 net loss rises 52% to EUR 42.2 million as cash falls 38% to EUR 92.4 million

Reuters
·
Mar 12

Market Chatter: Eli Lilly Expands in China with $3 Billion Supply Chain Investment

MT Newswires Live
·
Mar 12

Why Investors Aren't Fleeing to Safe-Haven Stocks -- Heard on the Street -- WSJ

Dow Jones
·
Mar 12

BUZZ-Abivax shares soar after renewed takeover rumours

Reuters
·
Mar 12

BRIEF-Eli Lilly Issues Warning About Potential Safety Risks Of Tirzepatide Compounded With Vitamin B12

Reuters
·
Mar 12

Eli Lilly: Has Notified the U.S. Food and Drug Administration (FDA) About These Findings

THOMSON REUTERS
·
Mar 12

Eli Lilly - Testing Uncovered Significant Levels of an Impurity That Results From a Chemical Reaction Between Tirzepatide and B12.

THOMSON REUTERS
·
Mar 12

Lilly: Continue to Find Other Critical Safety Issues in Compounded Tirzepatide Knockoffs, Including Bacterial Contamination, High Endotoxin Levels

THOMSON REUTERS
·
Mar 12

Eli Lilly: Urge FDA to Continue Taking Action Against Unlawful Mass Compounding of Tirzepatide That Puts the American Public at Risk- Website

THOMSON REUTERS
·
Mar 12

Eli Lilly: Potential for Dangerous Interactions Between Tirzepatide Compounded With Other Additives Remains Unknown

THOMSON REUTERS
·
Mar 12

an Open Letter From Eli Lilly and Company Warning of Potential Patient Safety Risks Associated With Tirzepatide Compounded With Vitamin B12

THOMSON REUTERS
·
Mar 12

Eli Lilly: Urge FDA to Continue Taking Action, Including by Requesting Recall of All Compounded Tirzepatide Combined With Untested Additives Like B12

THOMSON REUTERS
·
Mar 12

Eli Lilly Commits $3 Billion to Expand Weight-Loss Production in China

Stock News
·
Mar 12
More